{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:12:42Z","timestamp":1788581562386,"version":"build-2803163510"},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.2169\/internalmedicine.6599-25","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T22:26:44Z","timestamp":1766615204000},"page":"2352-2357","source":"Crossref","is-referenced-by-count":1,"title":["Severe Hypercholesterolemia Caused by Mesalazine Which Is a Key Drug of Ulcerative Colitis"],"prefix":"10.2169","volume":"65","author":[{"given":"Takatoshi","family":"Anno","sequence":"first","affiliation":[{"name":"Department of Diabetic Medicine, Kurashiki Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Diabetic Medicine, Kurashiki Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kaku","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kaneto","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kamei","sequence":"additional","affiliation":[{"name":"Department of Diabetic Medicine, Kurashiki Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. American Heart Association Statistics Committee; Stroke Statistics Subcommittee; Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics - 2016 Update: a report from the American Heart Association. Circulation 133: e38-e360, 2016."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Chaggar PS, Shaw SM, Williams SG. Effect of antipsychotic medications on glucose and lipid levels. J Clin Pharmacol 51: 631-638, 2011.","DOI":"10.1177\/0091270010368678"},{"key":"3","unstructured":"3. Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care 23: S139-S148, 2017."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Karpale M, Hukkanen J, Hakkola J. Nuclear receptor PXR in drug-induced hypercholesterolemia. Cells 11: 313, 2022.","DOI":"10.3390\/cells11030313"},{"key":"5","unstructured":"5. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63: 2889-2934, 2014."},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 51: 536-539, 2002.","DOI":"10.1136\/gut.51.4.536"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA technical review on the management of mild-to-moderate ulcerative colitis. Gastroenterology 156: 769-808.e29, 2019.","DOI":"10.1053\/j.gastro.2018.12.008"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Vishwanath R, Hemphill LC. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. J Clin Lipidol 8: 18-28, 2014.","DOI":"10.1016\/j.jacl.2013.11.002"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sjouke B, Hovingh GK, Kastelein JJ, Stefanutti C. Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives. Curr Opin Lipidol 26: 200-209, 2015.","DOI":"10.1097\/MOL.0000000000000179"},{"key":"10","unstructured":"10. Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel. J Am Coll Cardiol 72: 662-680, 2018."},{"key":"11","unstructured":"11. Tromp TR, Hartgers ML, Hovingh GK, et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet 399: 719-728, 2022."},{"key":"12","unstructured":"12. Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41: 111-188, 2020."},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. US Preventive Services Task Force; Mangione CM, Barry MJ, Nicholson WK, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA 328: 746-753, 2022.","DOI":"10.1001\/jama.2022.13044"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19: 117-125, 2005.","DOI":"10.1111\/j.1472-8206.2004.00299.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 100: 363-370, 2015.","DOI":"10.1210\/jc.2014-3421"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Agarwal A, Prasad GV. Post-transplant dyslipidemia: mechanisms, diagnosis and management. World J Transplant 6: 125-134, 2016.","DOI":"10.5500\/wjt.v6.i1.125"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kockx M, Glaros E, Leung B, et al. Low-density lipoprotein receptor-dependent and low-density lipoprotein receptor-independent mechanisms of cyclosporin A-induced dyslipidemia. Arterioscler Thromb Vasc Biol 36: 1338-1349, 2016.","DOI":"10.1161\/ATVBAHA.115.307030"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Holdaas H, Potena L, Saliba F. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? Transplant Rev (Orlando) 29: 93-102, 2015.","DOI":"10.1016\/j.trre.2014.08.003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Bakan I, Laplante M. Connecting mTORC1 signaling to SREBP-1 activation. Curr Opin Lipidol 23: 226-234, 2012.","DOI":"10.1097\/MOL.0b013e328352dd03"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Cai HL, Tan QY, Jiang P, et al. A potential mechanism underlying atypical antipsychotics-induced lipid disturbances. Transl Psychiatry 5: e661, 2015.","DOI":"10.1038\/tp.2015.161"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Feeney ER, Mallon PW. HIV and HAART-associated dyslipidemia. Open Cardiovasc Med J 5: 49-63, 2011.","DOI":"10.2174\/1874192401105010049"},{"key":"22","unstructured":"22. Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis - the Third National Health and Nutrition Examination Survey. J Rheumatol 32: 2311-2316, 2005."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment - a prospective, controlled study. Arthritis Res Ther 8: R82, 2006.","DOI":"10.1186\/ar1952"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Robertson J, Peters MJ, McInnes IB, Sattar N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 9: 513-523, 2013.","DOI":"10.1038\/nrrheum.2013.91"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Heslinga SC, Peters MJ, Ter Wee MM, et al. Reduction of inflammation drives lipid changes in ankylosing spondylitis. J Rheumatol 42: 1842-1845, 2015.","DOI":"10.3899\/jrheum.150193"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Alarfaj SJ, El-Haggar SM, Hegazy SK, et al. Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: a randomized controlled pilot study. Front Med (Lausanne) 11: 1490178, 2025.","DOI":"10.3389\/fmed.2024.1490178"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/17\/65_6599-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:31:14Z","timestamp":1788579074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/17\/65_6599-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":26,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6599-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"6599-25"}}